ArticleInternational journal of surgery (London, England)2026
The disparity and trend of childhood cancer burden in survival perspective: a systematic analysis for the global burden of disease 2021.
Article in International journal of surgery (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe World Health Organization Global Initiative for Childhood Cancer has set a target of achieving a 60% survival rate by 2030. However, current evidence is insufficient to guide governments and medical institutions in developing the necessary policies and interventions to reach this goal. Therefore, it is imperative to systematically evaluate the current status and trends of childhood cancer survival worldwide.
methodsFocusing on mortality-to-incidence ratio (MIR), disability-adjusted life-years (DALY), and death, the study described the distribution and trends of these survival related indicators for childhood cancer using the data from GBD2021. The study characterized the disease spectrum of childhood cancer in Sociodemographic Index (SDI) regions and predicted the future trend using ARIMA mo MIR reflected the disparities in global countries and regions; Jointpoint model and age-period-cohort model were used to analyze the long-term trend; finally, the DALY of childhood cancer contribute to risk factors was assessed.
resultsIn 2021, 25 level 3 childhood cancers contributed to 114.50 thousand (95% UI 104.70-124.31) death and 9343.21 thousand (95% UI 8529.00-10157.41) DALYs globally, and the MIR was 0.41 (IQR 0.26-0.58). In the high SDI region, brain and central nervous system cancers have ranked first in age-standardized DALY rate (AS-DALY) and age-standardized death rate (ASDR), and it is estimated that the AS-DALYs of nervous system cancer likely to surpass those of hematologic malignancy by 2024. The childhood cancer burden decreased with increasing SDI levels. The largest MIR [31.83 (95%UI 20.38-53.14)] between low and high SDI region was observed in eye cancer, followed by testicular cancer, Hodgkin lymphoma, and malignant skin melanoma (MIR > 10) in 2021. There has been a global downward trend in AS-DALYs and ASDR for childhood cancer; however, breast cancer has been increasing continuously. Although the number, rate, period risk, and cohort risks for childhood cancer DALY decreased across all SDI regions, the absolute burden increased by 35.92% (95% CI: 11.64 to 67.70) in low SDI region, with a concurrently observed rise in the absolute value and risks for nervous system cancer. Besides, the DALY rate of liver cancer attributable to drug use consistently increased, especially in high SDI region.
conclusionThis study identified several key points newly and could contribute to more precise recommendations for childhood cancer healthcare. It is imperative to pay more attention to the first rank on DALY of brain and central nervous system cancer in high SDI region, setting the priority to narrow the burden gap on retinoblastoma, testicular cancer, Hodgkin lymphoma, and malignant cutaneous melanoma through conducting more economical and inclusive interventions worldwide. Also, breast cancer and drug use-induced liver cancer should not be ignored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.